

**DRAFT AGENDA**

<b>12:30</b>	<b>Light Lunch &amp; Registration</b>
<b>1:30</b>	<b>HBV Forum 5 Opening</b> <b>Forum Moderator:</b> Veronica Miller, <i>The Forum for Collaborative Research</i>
1:30	<b>Welcome and Introduction</b> Ryan Anderson, <i>The Forum for Collaborative Research</i> Harry Janssen, <i>Toronto Centre for Liver Disease, University Health Network</i> Anuj Gaggar, <i>Gilead</i>
<b>1:40</b>	<b>Session I: Insights and Challenges in Drug Development for Treating Hepatitis Delta</b> <b>Session Co-Moderator:</b> Marion Peters, <i>University of California, San Francisco</i>
1:45	<b>HDV Therapy - Relevant Recent Findings and Suggested Endpoints</b> Jeffrey Glenn, <i>Stanford University Medical Center</i>
1:55	<b>Molecular Insights into the Synergisms between IFN and the Entry Inhibitor Myrcludex B</b> Stephan Urban, <i>University Hospital Heidelberg</i>
2:05	<b>Clinical Challenges in the Development of HDV Infection</b> Heiner Wedemeyer, <i>Essen University Hospital</i>
2:15	<b>Panel Discussion</b> Eric Donaldson, <i>U.S. Food and Drug Administration</i> Jeffrey Glenn, <i>Stanford University Medical Center</i> Stephan Urban, <i>University Hospital Heidelberg</i> Heiner Wedemeyer, <i>Essen University Hospital</i> Gabriel Westman, <i>Swedish Medical Products Agency</i>
<b>3:00</b>	<b>Session II: HBV Forum Working Group Updates</b>
3:00	<b>Surrogate Endpoints Working Group Update</b> Marion Peters, <i>University of California, San Francisco</i>
3:10	<b>Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis</b> Ryan Anderson, <i>The Forum for Collaborative Research</i>
<b>3:30</b>	<b>Break</b>
4:00	<b>Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel</b> Maria Beumont-Mauviel, <i>Janssen Pharmaceuticals</i>
4:20	<b>Immune Monitoring Working Group Update</b> Sara Ferrando-Martinez, <i>AstraZeneca</i>
4:40	<b>Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection</b> <b>Session Co-Moderator:</b> Bruce Given, <i>Arrowhead Pharmaceuticals</i>
4:45	<b>Expert Perspectives, Relevant Recent Findings, and Panel Discussion</b> Stephanie Buchholz, <i>Federal Institute for Drugs and Medical Devices (BfArM)</i> Russell Fleischer, <i>U.S. Food and Drug Administration</i> Harry Janssen, <i>Toronto Centre for Liver Disease, University Health Network</i> Su Wang, <i>World Hepatitis Alliance, Hepatitis B Foundation</i>
5:55	<b>Wrap Up</b> Veronica Miller, <i>The Forum for Collaborative Research</i>
<b>6:00</b>	<b>Adjourn and Evening Networking Reception</b>